Laboratorios Farmaceuticos Rovi Statistics
Total Valuation
Laboratorios Farmaceuticos Rovi has a market cap or net worth of GBP 2.68 billion. The enterprise value is 2.78 billion.
Market Cap | 2.68B |
Enterprise Value | 2.78B |
Important Dates
The last earnings date was Thursday, November 7, 2024.
Earnings Date | Nov 7, 2024 |
Ex-Dividend Date | Jul 8, 2024 |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 18.61M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.01, with an EV/FCF ratio of 50.67.
EV / Earnings | 20.23 |
EV / Sales | 4.18 |
EV / EBITDA | 14.01 |
EV / EBIT | 15.73 |
EV / FCF | 50.67 |
Financial Position
The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.23.
Current Ratio | 2.50 |
Quick Ratio | 0.92 |
Debt / Equity | 0.23 |
Debt / EBITDA | 0.54 |
Debt / FCF | 1.95 |
Interest Coverage | 69.72 |
Financial Efficiency
Return on equity (ROE) is 29.65% and return on invested capital (ROIC) is 20.37%.
Return on Equity (ROE) | 29.65% |
Return on Assets (ROA) | 15.55% |
Return on Capital (ROIC) | 20.37% |
Revenue Per Employee | 315,059 |
Profits Per Employee | 65,042 |
Employee Count | 2,111 |
Asset Turnover | 0.94 |
Inventory Turnover | 0.87 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.61% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +20.61% |
50-Day Moving Average | 72.09 |
200-Day Moving Average | 79.07 |
Relative Strength Index (RSI) | 33.83 |
Average Volume (20 Days) | 5,224 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of GBP 665.09 million and earned 137.30 million in profits. Earnings per share was 2.57.
Revenue | 665.09M |
Gross Profit | 406.85M |
Operating Income | 176.89M |
Pretax Income | 176.19M |
Net Income | 137.30M |
EBITDA | 194.63M |
EBIT | 176.89M |
Earnings Per Share (EPS) | 2.57 |
Balance Sheet
The company has 14.61 million in cash and 106.74 million in debt, giving a net cash position of -92.14 million.
Cash & Cash Equivalents | 14.61M |
Total Debt | 106.74M |
Net Cash | -92.14M |
Net Cash Per Share | n/a |
Equity (Book Value) | 464.49M |
Book Value Per Share | 8.55 |
Working Capital | 276.55M |
Cash Flow
In the last 12 months, operating cash flow was 105.00 million and capital expenditures -50.20 million, giving a free cash flow of 54.80 million.
Operating Cash Flow | 105.00M |
Capital Expenditures | -50.20M |
Free Cash Flow | 54.80M |
FCF Per Share | n/a |
Margins
Gross margin is 61.17%, with operating and profit margins of 26.60% and 20.64%.
Gross Margin | 61.17% |
Operating Margin | 26.60% |
Pretax Margin | 26.49% |
Profit Margin | 20.64% |
EBITDA Margin | 29.26% |
EBIT Margin | 26.60% |
FCF Margin | 8.24% |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.20%.
Dividend Per Share | 0.75 |
Dividend Yield | 1.20% |
Dividend Growth (YoY) | -16.25% |
Years of Dividend Growth | 4 |
Payout Ratio | 34.21% |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | 4.92% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Laboratorios Farmaceuticos Rovi has an Altman Z-Score of 9.95.
Altman Z-Score | 9.95 |
Piotroski F-Score | n/a |